---
title: "Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study"
description: "Amgen and Kyowa Kirin announced positive results from their Phase 3 trials for rocatinlimab, a treatment for moderate to severe atopic dermatitis. The IGNITE study showed that 42.3% of patients in the"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231254076.md"
published_at: "2025-03-10T16:50:53.000Z"
---

# Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

> Amgen and Kyowa Kirin announced positive results from their Phase 3 trials for rocatinlimab, a treatment for moderate to severe atopic dermatitis. The IGNITE study showed that 42.3% of patients in the higher dose group achieved a significant reduction in eczema severity compared to placebo. The SHUTTLE study also met its endpoints, with 52.3% of patients in the higher dose group achieving similar results. Analysts suggest that these findings validate the OX40 mechanism and indicate a potential commercial opportunity for rocatinlimab in the market.

On Saturday, **Amgen Inc** AMGNand **Kyowa Kirin Co., Ltd.** announced new results from the ongoing ROCKET Phase 3 trial program rocatinlimab in moderate to severe atopic dermatitis (AD).

The IGNITE study evaluated two dose strengths of rocatinlimab and met its co-primary endpoints and all key secondary endpoints versus placebo.

-   At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo, and 36.3% vs. 23.4% in the lower dose group.
-   In the higher dose group, 23.6% of patients achieved a validated Investigator’s Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 24, representing a 14.9% difference vs. placebo.
-   In the lower dose group, 19.1% of patients achieved this endpoint, a 10.3% difference vs. placebo.

**Also Read: Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials**

In addition, IGNITE met the endpoint of the revised Investigator’s Global (rIGA) Assessment score of 0/1 with a ≥2-point reduction from baseline.

-   At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4% difference vs. placebo.
-   In the lower dose group, 16.3% of patients achieved this endpoint, an 8.0% difference vs. placebo.

The ROCKET program is also informed by the results of the SHUTTLE and VOYAGER studies.

-   The SHUTTLE study evaluated two dose strengths of rocatinlimab in combination with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI) in 746 adults using the same co-primary endpoints as IGNITE. The study met its co-primary and all key secondary endpoints.
    -   For EASI-75, 52.3% of patients in SHUTTLE’s higher dose group achieved the endpoint, a 28.7% difference vs. placebo, while 54.1% of patients in the lower dose group achieved the endpoint, a 30.4% difference vs. placebo.
    -   For vIGA-AD 0/1, 26.1% of SHUTTLE patients in the higher dose group achieved the endpoint, a 13.8% difference vs. placebo. In the lower dose group: 25.8% vs. 13.5%.
    -   For rIGA 0/1, 23.3% of SHUTTLE patients in the higher dose group achieved the endpoint, an 11.5% difference vs. placebo and 22.7% vs. 10.9% in the lower dose group.

The VOYAGER study demonstrated that rocatinlimab does not interfere with responses to tetanus and meningococcal vaccinations.

William Blair writes rocatinlimab results validate the OX40 mechanism, likely supporting a moderate commercial opportunity for patients after **Sanofi SA** SNY and **Regeneron Pharmaceutical Inc’s** REGN Dupixent and **Eli Lilly & Co’s** LLY Ebglyss.

**Price Action:** AMGN stock is up 2.4% at $332.90 at last check Monday.

**Read Next:**

-   **India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details**

*Photo: Shutterstock*

### Related Stocks

- [AMGN.US - Amgen](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 安進｜8-K：2025 財年 Q4 營收 98.66 億美元超過預期 |  | [Link](https://longbridge.com/en/news/274709467.md) |
| 對安進 2025 年第四季度財報的預期 | 安進 2025 年第四季度財報的預期 | [Link](https://longbridge.com/en/news/271647537.md) |
| 分析師的判決：18 位專家眼中的安進 | 安進（NASDAQ:AMGN）在過去三個月內獲得了 18 位分析師的混合評級，平均 12 個月目標價為 350.61 美元，比之前的目標上漲了 6.93%。分析師們提高了他們的評級和目標價，其中富國銀行和派珀·桑德勒等公司的增幅尤為顯著。安 | [Link](https://longbridge.com/en/news/276494592.md) |
| 安進在花旗峯會上詳細介紹了其在腫瘤研發方面的推進、IMDELLTRA 的擴展以及 LUMAKRAS 的最新進展 | 安進的高管在花旗的虛擬腫瘤領導峯會上介紹了公司的腫瘤研發優先事項和關鍵項目的最新進展。他們強調了針對難治性腫瘤的差異化療法，重點關注 T 細胞連接劑和精準小分子。更新內容包括 IMDELLTRA 在小細胞肺癌中的推出、正在進行的三期臨牀試驗 | [Link](https://longbridge.com/en/news/276288691.md) |
| 儘管安進公司股票週三有所上漲，但與競爭對手相比表現不佳 | 安進（Amgen Inc.，股票代碼：AMGN）週三股價上漲 1.44%，至 328.97 美元，打破了連續四天的下跌趨勢，儘管整體市場下滑，標準普爾 500 指數下跌 0.53%。然而，安進的表現仍落後於競爭對手，如強生（Johnson  | [Link](https://longbridge.com/en/news/272605226.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.